In our material, it allowed the identification of 92.9% of cancers negative for rFNA, EU-TIRADS and BRAF mutation, including all cancers corresponding to AUS-other nodules and 85.7% of cancers corresponding to AUS-nuclear nodules. The gene discussed is BRAF; the disease is cancer.